language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
UTMDUTMD

$60.24

+1.32
arrow_drop_up2.24%
Current Market·update15 Jan 2026 16:50
Day's Range
59.435-60.24
52-week Range
51.26-65.56

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-10-23
Next Earnings TimeBefore Market Open
Volume3.02K
Average Volume 30d12.95K

AI UTMD Summary

Powered by LiveAI
💰
20
Valuation (P/E Ratio)
Reasonable P/E TTM, but quarterly P/E suggests potential overvaluation
📈
0.152
EPS Growth (YoY)
Positive year-over-year EPS growth from 2023 to 2024
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
75

Utah Medical Products exhibits a solid fundamental profile with consistent profitability and a strong balance sheet. Thematic tailwinds in healthcare technology support long-term growth, although recent technical indicators suggest a period of consolidation. Overall, it presents a compelling investment opportunity for patient investors.

Moderate

Thematic

70

Utah Medical Products operates in the healthcare technology sector, benefiting from trends in medical device innovation and an aging global population. While it holds a niche, the company's growth is tied to specific medical applications rather than broad, disruptive themes like AI.

Strong

Fundamental

85

Utah Medical Products demonstrates strong financial health with consistent profitability, healthy margins, and a robust balance sheet characterized by ample cash and low debt. Its valuation metrics are reasonable given its performance.

Neutral to Slightly Bearish Short-Term

Technical

65

The stock is trading above its key long-term moving averages, suggesting an underlying bullish trend. However, recent performance shows a significant drop (-10.75% post-market), and several short-term technical indicators are mixed, pointing towards potential short-term volatility or consolidation.

FactorScore
Healthcare Technology Adoption75
Aging Population & Chronic Diseases65
Innovation in Medical Devices80
Regulatory Landscape (Healthcare)60
Market Niche Focus70
FactorScore
Valuation70
Profitability95
Growth30
Balance Sheet Health100
Cash Flow80
FactorScore
Trend Analysis75
Momentum60
Volume Confirmation60
Support & Resistance60
Recent Performance70

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Valuation chevron_right

Favorable P/E Ratio

The trailing Price-to-Earnings (P/E) ratio of 15.65 is below the industry average of 18, suggesting potential undervaluation relative to peers.

Performance chevron_right

Positive Short-Term Performance

The stock has shown positive performance over the last 5 days (+3.74%) and 1 month (+1.3%), indicating recent positive investor sentiment.

Show More 🔒
thumb_down

Bearish Points (7)

Performance chevron_right

Negative Long-Term Performance

The stock has experienced negative performance over the last 6 months (-7.76%) and 1 year (-13.13%), indicating recent underperformance and potential headwinds.

Technical Analysis chevron_right

Bearish Moving Average Signals

Several key moving averages, including the 10-day and 20-day EMAs and SMAs, are signaling 'Sell', suggesting potential downward price pressure.

Show More 🔒

Calendar

June 2025

16

Ex-Dividend Date

July 2025

3

Next Dividend Date

July 2025

24

Next Earnings Date

EPS Est.
Revenue Est.

H: $

A: $

L: $

Profile

Employees (FY)155
ISINUS9174881089
FIGI-

Utah Medical Products, Inc. provides medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company also provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. The company serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Seasonals

2025
2024
2023
2022
2021

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
2.8M (86.26%)
Closely held shares
446K (13.74%)
3.25M
Free Float shares
2.8M (86.26%)
Closely held shares
446K (13.74%)

Capital Structure

Market cap
190.17M
Debt
282K
Minority interest
0.00
Cash & equivalents
82.98M
Enterprise value
107.47M

Valuation - Summary

Market Cap
190M
Net income
9.51M(5.00%)
Revenue
28.9M(15.18%)
190M
Market Cap
190M
Net income
9.51M(5.00%)
Revenue
28.9M(15.18%)
Price to earning ratio (P/E)20.00x
Price to sales ratio (P/S)6.60x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
40.9M
COGS
16.76M
Gross Profit
24.14M
OpEx
10.55M
Operating Income
13.59M
Other & Taxes
-280K
Net Income
13.87M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒